Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections

Frontiers in Microbiology

Volumn 9, Issue JUN, 2018, Pages

  Baktash, Amoe ^a   Terveer, Elisabeth M ^a,b   Zwittink, Romy D ^a   Hornung, Bastian V H ^a   Corver, Jeroen ^a   Kuijper, Ed J ^a,b   Smits, Wiep Klaas ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Donor Feces Bank   (Netherlands)

Author keywords

Antimicrobial peptides; Bacteriocins; Bacteriophages; Bile acids; Clostridium difficile infection; Fecal microbiota transplant; Short chain fatty acids; Sialic acids

Indexed keywords

BILE ACID; MEDIUM CHAIN FATTY ACID; SHORT CHAIN FATTY ACID;

BACTERIAL COLONIZATION; BACTERIOPHAGE; BIOLOGICAL WARFARE; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANTATION; NONHUMAN; NUTRIENT; PEPTOCLOSTRIDIUM DIFFICILE; PLEIOTROPY; REVIEW;

EID: 85048309356     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.01242     Document Type: Review

References (184)

1. Abedon, S. T. (2017). Bacteriophage clinical use as antibacterial 'drugs': utility and precedent. Microbiol. Spectr. 5:4. doi: 10.1128/microbiolspec.BAD-0003-2016
2. Allegretti, J. R., Kearney, S., Li, N., Bogart, E., Bullock, K., Gerber, G. K., et al. (2016). Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol. Ther. 43, 1142-1153. doi: 10.1111/apt.13616
3. Andersen, J. M., Shoup, M., Robinson, C., Britton, R., Olsen, K. E., and Barrangou, R. (2016). CRISPR diversity and microevolution in Clostridium difficile. Genome Biol. Evol. 8, 2841-2855. doi: 10.1093/gbe/evw203
4. Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., et al. (2013). Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51, 2884-2892. doi: 10.1128/JCM.00845-13
5. Atuma, C., Strugala, V., Allen, A., and Holm, L. (2001). The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G922-G929. doi: 10.1152/ajpgi.2001.280.5.G922
6. Bakker, D., Buckley, A. M., de Jong, A., van Winden, V. J., Verhoeks, J. P., Kuipers, O. P., et al. (2014). The HtrA-like protease CD3284 modulates virulence of Clostridium difficile. Infect. Immun. 82, 4222-4232. doi: 10.1128/IAI.02336-14
7. Bakker, G. J., and Nieuwdorp, M. (2017). Fecal microbiota transplantation: therapeutic potential for a multitude of diseases beyond Clostridium difficile. Microbiol. Spectr. 5:4. doi: 10.1128/microbiolspec.BAD-0008-2017
8. Bartlett, J. G. (2009). Clostridium difficile infection: historic review. Anaerobe 15, 227-229. doi: 10.1016/j.anaerobe.2009.09.004
9. Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., et al. (2011). Clostridium difficile infection in Europe: a hospital-based survey. Lancet 37, 63-73. doi: 10.1016/S0140-6736(10)61266-4
10. Belkaid, Y., and Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell 157, 121-141. doi: 10.1016/j.cell.2014.03.011
11. Bohnhoff, M., and Miller, C. P. (1962). Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J. Infect. Dis. 111, 117-127. doi: 10.1093/infdis/111.2.117
12. Boix, V., Fedorak, R. N., Mullane, K. M., Pesant, Y., Stoutenburgh, U., Jin, M., et al. (2017). Primary outcomes from a Phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect. Dis. 4:ofw275. doi: 10.1093/ofid/ofw275
13. Borriello, S. P., and Barclay, F. E. (1986). An in-vitro model of colonisation resistance to Clostridium difficile infection. J. Med. Microbiol. 21, 299-309. doi: 10.1099/00222615-21-4-299
14. Boudry, P., Semenova, E., Monot, M., Datsenko, K. A., Lopatina, A., Sekulovic, O., et al. (2015). Function of the CRISPR-Cas system of the human pathogen Clostridium difficile. mBio 6:e01112-15. doi: 10.1128/mBio.01112-15
15. Bouillaut, L., Dubois, T., Sonenshein, A. L., and Dupuy, B. (2015). Integration of metabolism and virulence in Clostridium difficile. Res. Microbiol. 166, 375-383. doi: 10.1016/j.resmic.2014.10.002
16. Britton, R. A., and Young, V. B. (2014). Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146, 1547-1553. doi: 10.1053/j.gastro.2014.01.059
17. Broecker, F., Russo, G., Klumpp, J., and Moelling, K. (2017). Stable core virome despite variable microbiome after fecal transfer. Gut Microbes 8, 214-220. doi: 10.1080/19490976.2016.1265196
18. Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., et al. (2015). Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205-208. doi: 10.1038/nature13828
19. Cammarota, G., Ianiro, G., Tilg, H., Rajilic-Stojanovic, M., Kump, P., Satokari, R., et al. (2017). European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569-580. doi: 10.1136/gutjnl-2016-313017
20. Castiglione, F., Lazzarini, A., Carrano, L., Corti, E., Ciciliato, I., Gastaldo, L., et al. (2008). Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem. Biol. 15, 22-31. doi: 10.1016/j.chembiol.2007.11.009
21. Chai, C., Lee, K. S., and Oh, S. W. (2015). Synergistic inhibition of Clostridium difficile with nisin-lysozyme combination treatment. Anaerobe 34, 24-26. doi: 10.1016/j.anaerobe.2015.04.003
22. Chandrasekaran, R., and Lacy, D. B. (2017). The role of toxins in Clostridium difficile infection. FEMS Microbiol. Rev. 41, 723-750. doi: 10.1093/femsre/fux048
23. Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., et al. (2008). Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435-438. doi: 10.1086/525047
24. Chang, T. W., Bartlett, J. G., Gorbach, S. L., and Onderdonk, A. B. (1978). Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect. Immun. 20, 526-529
25. Chehoud, C., Dryga, A., Hwang, Y., Nagy-Szakal, D., Hollister, E. B., Luna, R. A., et al. (2016). Transfer of viral communities between human individuals during fecal microbiota transplantation. mBio 7:e00322. doi: 10.1128/mBio.00322-16
26. Chen, T., Kim, C. Y., Kaur, A., Lamothe, L., Shaikh, M., Keshavarzian, A., et al. (2017). Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a Caco-2 cell model. Food Funct. 8, 1166-1173. doi: 10.1039/c6fo01532h
27. Chiang, J. Y. (2009). Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966. doi: 10.1194/jlr.R900010-JLR200
28. Chumbler, N. M., Rutherford, S. A., Zhang, Z., Farrow, M. A., Lisher, J. P., Farquhar, E., et al. (2016). Crystal structure of Clostridium difficile toxin A. Nat. Microbiol. 1:15002. doi: 10.1038/nmicrobiol.2015.2
29. Collins, F. W. J., O'Connor, P. M., O'Sullivan, O., Rea, M. C., Hill, C., and Ross, R. P. (2016). Formicin-a novel broad-spectrum two-component lantibiotic produced by Bacillus paralicheniformis APC 1576. Microbiology 162, 1662-1671. doi: 10.1099/mic.0.000340
30. Collins, J., Robinson, C., Danhof, H., Knetsch, C. W., van Leeuwen, H. C., Lawley, T. D., et al. (2018). Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 553, 291-294. doi: 10.1038/nature25178
31. Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., and Gorbach, S. L. (2012). Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55(Suppl. 2), S154-S161. doi: 10.1093/cid/cis462
32. Cowardin, C. A., and Petri, W. A. Jr. (2014). Host recognition of Clostridium difficile and the innate immune response. Anaerobe 30, 205-209. doi: 10.1016/j.anaerobe.2014.08.014
33. Crobach, M. J. T., Vernon, J. J., Loo, V. G., Kong, L. Y., Pechine, S., Wilcox, M. H., et al. (2018). Understanding Clostridium difficile colonization. Clin. Microbiol. Rev. 31:2e00021-17. doi: 10.1128/CMR.00021-17
34. Deakin, L. J., Clare, S., Fagan, R. P., Dawson, L. F., Pickard, D. J., West, M. R., et al. (2012). The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect. Immun. 80, 2704-2711. doi: 10.1128/IAI.00147-12
35. Debast, S. B., Bauer, M. P., Kuijper, E. J., and European Society of Clinical, Microbiology and Infectious, Diseases (2014). European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20(Suppl. 2), 1-26. doi: 10.1111/1469-0691.12418
36. den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., and Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325-2340. doi: 10.1194/jlr.R036012
37. Dethlefsen, L., and Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4554-4561. doi: 10.1073/pnas.1000087107
38. Dowah, A. S. A., and Clokie, M. R. J. (2018). Review of the nature, diversity and structure of bacteriophage receptor binding proteins that target Gram-positive bacteria. Biophys. Rev. 10, 535-542. doi: 10.1007/s12551-017-0382-3
39. Dupuy, B., and Sonenshein, A. L. (1998). Regulated transcription of Clostridium difficile toxin genes. Mol. Microbiol. 27, 107-120. doi: 10.1046/j.1365-2958.1998.00663.x
40. Eiseman, B., Silen, W., Bascom, G. S., and Kauvar, A. J. (1958). Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44, 854-859
41. Eyre, D. W., Griffiths, D., Vaughan, A., Golubchik, T., Acharya, M., O'Connor, L., et al. (2013). Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One 8:e78445. doi: 10.1371/journal.pone.0078445
42. Fekety, R., McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., and Mulligan, M. E. (1997). Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 24, 324-333. doi: 10.1093/clinids/24.3.324
43. Fernandez, L., Rodriguez, A., and Garcia, P. (2018). Phage or foe: an insight into the impact of viral predation on microbial communities. ISME J. 12, 1171-1179. doi: 10.1038/s41396-018-0049-5
44. Ferreyra, J. A., Wu, K. J., Hryckowian, A. J., Bouley, D. M., Weimer, B. C., and Sonnenburg, J. L. (2014). Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16, 770-777. doi: 10.1016/j.chom.2014.11.003
45. Fischer Walker, C., and Black, R. E. (2004). Zinc and the risk for infectious disease. Annu. Rev. Nutr. 24, 255-275. doi: 10.1146/annurev.nutr.23.011702.073054
46. Fletcher, J. R., Erwin, S., Lanzas, C., and Theriot, C. M. (2018). Shifts in the Gut metabolome and Clostridium difficile transcriptome throughout colonization and infection in a mouse model. mSphere 3:e00089-18. doi: 10.1128/mSphere.00089-18
47. Fortier, L. C. (2017). The contribution of bacteriophages to the biology and virulence of pathogenic clostridia. Adv. Appl. Microbiol. 101, 169-200. doi: 10.1016/bs.aambs.2017.05.002
48. Francis, M. B., Allen, C. A., Shrestha, R., and Sorg, J. A. (2013). Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 9:e1003356. doi: 10.1371/journal.ppat.1003356
49. Fuentes, S., Rossen, N. G., van der Spek, M. J., Hartman, J. H., Huuskonen, L., Korpela, K., et al. (2017). Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 11, 1877-1889. doi: 10.1038/ismej.2017.44
50. George, W. L., Sutter, V. L., Goldstein, E. J., Ludwig, S. L., and Finegold, S. M. (1978). Aetiology of antimicrobial-agent-associated colitis. Lancet 1, 802-803. doi: 10.1016/S0140-6736(78)93001-5
51. Giesemann, T., Guttenberg, G., and Aktories, K. (2008). Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 13, 2049-2058. doi: 10.1053/j.gastro.2008.03.008
52. Goh, S., Chang, B. J., and Riley, T. V. (2005). Effect of phage infection on toxin production by Clostridium difficile. J. Med. Microbiol. 54(Pt 2), 129-135. doi: 10.1099/jmm.0.45821-0
53. Goorhuis, A., Bakker, D., Corver, J., Debast, S. B., Harmanus, C., Notermans, D. W., et al. (2008). Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47, 1162-1170. doi: 10.1086/592257
54. Govind, R., Vediyappan, G., Rolfe, R. D., Dupuy, B., and Fralick, J. A. (2009). Bacteriophage-mediated toxin gene regulation in Clostridium difficile. J. Virol. 83, 12037-12045. doi: 10.1128/JVI.01256-09
55. Hafiz, S., and Oakley, C. L. (1976). Clostridium difficile: isolation and characteristics. J. Med. Microbiol. 9, 129-136. doi: 10.1099/00222615-9-2-129
56. Hall, I. C., and O'Toole, E. (1935). Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child 49, 390-402. doi: 10.1001/archpedi.1935.01970020105010
57. Hanchi, H., Hammami, R., Gingras, H., Kourda, R., Bergeron, M. G., Ben Hamida, J., et al. (2017). Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics. Fut. Microbiol. 12, 205-212. doi: 10.2217/fmb-2016-0113
58. Hargreaves, K. R., and Clokie, M. R. (2014). Clostridium difficile phages: still difficult? Front. Microbiol. 5:184. doi: 10.3389/fmicb.2014.00184
59. Hargreaves, K. R., and Clokie, M. R. (2015). A taxonomic review of Clostridium difficile phages and proposal of a novel genus, 'Phimmp04likevirus'. Viruses 7, 2534-2541. doi: 10.3390/v7052534
60. Hargreaves, K. R., Colvin, H. V., Patel, K. V., Clokie, J. J., and Clokie, M. R. (2013). Genetically diverse Clostridium difficile strains harboring abundant prophages in an estuarine environment. Appl. Environ. Microbiol. 79, 6236-6243. doi: 10.1128/AEM.01849-13
61. Hargreaves, K. R., Flores, C. O., Lawley, T. D., and Clokie, M. R. (2014a). Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogen. mBio 5:e01045-13. doi: 10.1128/mBio.01045-13
62. Hargreaves, K. R., Kropinski, A. M., and Clokie, M. R. (2014b). Bacteriophage behavioral ecology: how phages alter their bacterial host's habits. Bacteriophage 4:e29866. doi: 10.4161/bact.29866
63. Hastie, J. L., Williams, K. B., Sepulveda, C., Houtman, J. C., Forest, K. T., and Ellermeier, C. D. (2014). Evidence of a bacterial receptor for lysozyme: binding of lysozyme to the anti-sigma factor RsiV controls activation of the ecf sigma factor sigmaV. PLoS Genet. 10:e1004643. doi: 10.1371/journal.pgen.1004643
64. Hatziioanou, D., Gherghisan-Filip, C., Saalbach, G., Horn, N., Wegmann, U., Duncan, S. H., et al. (2017). Discovery of a novel lantibiotic nisin O from Blautia obeum A2-162, isolated from the human gastrointestinal tract. Microbiology 163, 1292-1305. doi: 10.1099/mic.0.000515
65. He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin, M. J., et al. (2013). Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109-113. doi: 10.1038/ng.2478
66. Hensgens, M. P., Goorhuis, A., Dekkers, O. M., and Kuijper, E. J. (2012). Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J. Antimicrob. Chemother. 67, 742-748. doi: 10.1093/jac/dkr508
67. Hing, T. C., Ho, S., Shih, D. Q., Ichikawa, R., Cheng, M., Chen, J., et al. (2013). The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 62, 1295-1305. doi: 10.1136/gutjnl-2012-302180
68. Hopkins, M. J., and Macfarlane, G. T. (2003). Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl. Environ. Microbiol. 69, 1920-1927. doi: 10.1128/AEM.69.4.1920-1927.2003
69. Hryckowian, A. J., Pruss, K. M., and Sonnenburg, J. L. (2017). The emerging metabolic view of Clostridium difficile pathogenesis. Curr. Opin. Microbiol. 35, 42-47. doi: 10.1016/j.mib.2016.11.006
70. Hryckowian, A. J., Van Treuren, W., Smits, S. A., Davis, N. M., Gardner, J. O., Bouley, D. M., et al. (2018). Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model. Nat. Microbiol. 3, 662-669. doi: 10.1038/s41564-018-0150-6
71. Islam, K. B., Fukiya, S., Hagio, M., Fujii, N., Ishizuka, S., Ooka, T., et al. (2011). Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141, 1773-781. doi: 10.1053/j.gastro.2011.07.04
72. Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., et al. (2014). Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 59, 345-354. doi: 10.1093/cid/ciu313
73. Kakiyama, G., Pandak, W. M., Gillevet, P. M., Hylemon, P. B., Heuman, D. M., Daita, K., et al. (2013). Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58, 949-955. doi: 10.1016/j.jhep.2013.01.003
74. Karasawa, T., Ikoma, S., Yamakawa, K., and Nakamura, S. (1995). A defined growth medium for Clostridium difficile. Microbiology 141(Pt 2), 371-375. doi: 10.1099/13500872-141-2-371
75. Karlsson, S., Burman, L. G., and Akerlund, T. (1999). Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145(Pt 7), 1683-1693. doi: 10.1099/13500872-145-7-1683
76. Keller, J. J., and Kuijper, E. J. (2015). Treatment of recurrent and severe Clostridium difficile infection. Annu. Rev. Med. 66, 373-386. doi: 10.1146/annurev-med-070813-114317
77. Khoruts, A., and Sadowsky, M. J. (2016). Understanding the mechanisms of faecal microbiota transplantation. Nat. Rev. Gastroenterol. Hepatol. 13, 508-516. doi: 10.1038/nrgastro.2016.98
78. Kirk, J. A., Gebhart, D., Buckley, A. M., Lok, S., Scholl, D., Douce, G. R., et al. (2017). New class of precision antimic robials redefines role of Clostridium difficile S-layer in virulence and viability. Sci. Transl. Med. 9:eaah6813. doi: 10.1126/scitranslmed.aah6813
79. Knight-Connoni, V., Mascio, C., Chesnel, L., and Silverman, J. (2016). Discovery and development of surotomycin for the treatment of Clostridium difficile. J. Ind. Microbiol. Biotechnol. 43, 195-204. doi: 10.1007/s10295-015-1714-6
80. Kochan, T. J., Somers, M. J., Kaiser, A. M., Shoshiev, M. S., Hagan, A. K., Hastie, J. L., et al. (2017). Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores. PLoS Pathog. 13:e1006443. doi: 10.1371/journal.ppat.1006443
81. Kociolek, L. K., and Gerding, D. N. (2016). Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 13, 150-160. doi: 10.1038/nrgastro.2015.220
82. Konturek, P. C., Koziel, J., Dieterich, W., Haziri, D., Wirtz, S., Glowczyk, I., et al. (2016). Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J. Physiol. Pharmacol. 67, 859-866
83. Lamendella, R., Wright, J. R., Hackman, J., McLimans, C., Toole, D. R., Bernard Rubio, W., et al. (2018). Antibiotic Treatments for Clostridium difficile Infection Are associated with distinct bacterial and fungal community structures. mSphere 3:e00572-17. doi: 10.1128/mSphere.00572-17
84. Larson, H. E., Price, A. B., Honour, P., and Borriello, S. P. (1978). Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1, 1063-1066. doi: 10.1016/S0140-6736(78)90912-1
85. Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., et al. (2012). Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8:e1002995. doi: 10.1371/journal.ppat.1002995
86. Lawley, T. D., and Walker, A. W. (2013). Intestinal colonization resistance. Immunology 138, 1-11. doi: 10.1111/j.1365-2567.2012.03616.x
87. Lawson, P. A., Citron, D. M., Tyrrell, K. L., and Finegold, S. M. (2016). Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole, 1935) Prevot 1938. Anaerobe 40, 95-99. doi: 10.1016/j.anaerobe.2016.06.008
88. Le Lay, C., Dridi, L., Bergeron, M. G., Ouellette, M., and Fliss, I. L. (2016). Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J. Med. Microbiol. 65, 169-175. doi: 10.1099/jmm.0.000202
89. Le Lay, C., Fernandez, B., Hammami, R., Ouellette, M., and Fliss, I. (2015). On Lactococcus lactis UL719 competitivity and nisin (Nisaplin((R))) capacity to inhibit Clostridium difficile in a model of human colon. Front. Microbiol. 6:1020. doi: 10.3389/fmicb.2015.01020
90. Lewin, R. A. (1999). Merde: Excursions in Scientific, Cultural and Socio-Historical Coprology. New York, NY: Random House
91. Ling, Z., Liu, X., Jia, X., Cheng, Y., Luo, Y., and Yuan, L., et al. (2014). Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci. Rep. 4:7485. doi: 10.1038/srep07485
92. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431. doi: 10.1056/NEJMoa0910812
93. Lubelski, J., Rink, R., Khusainov, R., Moll, G. N., and Kuipers, O. P. (2008). Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol. Life Sci. 65, 455-476. doi: 10.1007/s00018-007-7171-2
94. Manrique, P., Dills, M., and Young, M. J. (2017). The human gut phage community and its implications for health and disease. Viruses 9:141. doi: 10.3390/v9060141
95. Marcobal, A., Barboza, M., Sonnenburg, E. D., Pudlo, N., Martens, E. C., Desai, P., et al. (2011). Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe 10, 507-514. doi: 10.1016/j.chom.2011.10.007
96. Marcobal, A., Southwick, A. M., Earle, K. A., and Sonnenburg, J. L. (2013). A refined palate: bacterial consumption of host glycans in the gut. Glycobiology 23, 1038-1046. doi: 10.1093/glycob/cwt040
97. Martin-Verstraete, I., Peltier, J., and Dupuy, B. (2016). The regulatory networks that control Clostridium difficile toxin synthesis. Toxins 8:153. doi: 10.3390/toxins8050153
98. Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., et al. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282-1286. doi: 10.1038/nature08530
99. May, T., Mackie, R. I., Fahey, G. C. Jr., Cremin, J. C., and Garleb, K. A. (1994). Effect of fiber source on short-chain fatty acid production and on the growth and toxin production by Clostridium difficile. Scand. J. Gastroenterol. 29, 916-922. doi: 10.3109/00365529409094863
100. Mayer, M. J., Garefalaki, V., Spoerl, R., Narbad, A., and Meijers, R. (2011). Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J. Bacteriol. 193, 5477-5486. doi: 10.1128/JB.00439-11
101. McBride, S. M., and Sonenshein, A. L. (2011a). Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect. Immun. 79, 167-176. doi: 10.1128/IAI.00731-10
102. McBride, S. M., and Sonenshein, A. L. (2011b). The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 157(Pt 5), 1457-1465. doi: 10.1099/mic.0.045997-0
103. McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., et al. (2018). Clinical practice guidelines for Clostridium difficile Infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, 987-994. doi: 10.1093/cid/ciy149
104. McQuade, R., Roxas, B., Viswanathan, V. K., and Vedantam, G. (2012). Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. Anaerobe 18, 614-620. doi: 10.1016/j.anaerobe.2012.09.004
105. Meader, E., Mayer, M. J., Gasson, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2010). Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16, 549-554. doi: 10.1016/j.anaerobe.2010.08.006
106. Meader, E., Mayer, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2013). Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22, 25-30. doi: 10.1016/j.anaerobe.2013.05.001
107. Meessen-Pinard, M., Sekulovic, O., and Fortier, L. C. (2012). Evidence of in vivo prophage induction during Clostridium difficile infection. Appl. Environ. Microbiol. 78, 7662-7670. doi: 10.1128/AEM.02275-12
108. Mirzaei, M. K., and Maurice, C. F. (2017). Menage a trois in the human gut: interactions between host, bacteria and phages. Nat. Rev. Microbiol. 15, 397-408. doi: 10.1038/nrmicro.2017.30
109. Moayyedi, P., Yuan, Y., Baharith, H., and Ford, A. C. (2017). Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med. J. Aust. 207, 166-172. doi: 10.5694/mja17.00295
110. Modi, S. R., Lee, H. H., Spina, C. S., and Collins, J. J. (2013). Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 499, 219-222. doi: 10.1038/nature12212
111. Moore, J. H., Pinheiro, C. C., Zaenker, E. I., Bolick, D. T., Kolling, G. L., van Opstal, E., et al. (2015). Defined nutrient diets alter susceptibility to Clostridium difficile associated disease in a murine model. PLoS One 10:e0131829. doi: 10.1371/journal.pone.0131829
112. Nale, J. Y., Chutia, M., Carr, P., Hickenbotham, P. T., and Clokie, M. R. (2016a). 'Get in Early'; biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front. Microbiol. 7:1383. doi: 10.3389/fmicb.2016.01383
113. Nale, J. Y., Redgwell, T. A., Millard, A., and Clokie, M. R. J. (2018). Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model. Antibiotics 7:13. doi: 10.3390/antibiotics7010013
114. Nale, J. Y., Spencer, J., Hargreaves, K. R., Buckley, A. M., Trzepinski, P., Douce, G. R., et al. (2016b). Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60, 968-981. doi: 10.1128/AAC.01774-15
115. Nawrocki, K. L., Wetzel, D., Jones, J. B., Woods, E. C., and McBride, S. M. (2018). Ethanolamine is a valuable nutrient source that impacts Clostridium difficile pathogenesis. Environ. Microbiol. 20, 1419-1435. doi: 10.1111/1462-2920.14048
116. Ng, K. M., Ferreyra, J. A., Higginbottom, S. K., Lynch, J. B., Kashyap, P. C., Gopinath, S., et al. (2013). Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502, 96-99. doi: 10.1038/nature12503
117. Nuding, S., Frasch, T., Schaller, M., Stange, E. F., and Zabel, L. T. (2014). Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile. Antimicrob. Agents Chemother. 58, 5719-5725. doi: 10.1128/AAC.02542-14
118. Ofir, G., and Sorek, R. (2018). Contemporary phage biology: from classic models to new insights. Cell 172, 1260-1270. doi: 10.1016/j.cell.2017.10.045
119. Oliveira Paiva, A. M., Friggen, A. H., Hossein-Javaheri, S., and Smits, W. K. (2016). The signal sequence of the abundant extracellular metalloprotease PPEP-1 can be used to secrete synthetic reporter proteins in Clostridium difficile. ACS Synth. Biol. 5, 1376-1382. doi: 10.1021/acssynbio.6b00104
120. Ooijevaar, R. E., van Beurden, Y. H., Terveer, E. M., Goorhuis, A., Bauer, M. P., Keller, J. J., et al. (2018). Update of treatment algorithms for Clostridium difficile infection. Clin. Microbiol. Infect. 24, 452-462. doi: 10.1016/j.cmi.2017.12.022
121. Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., et al. (2017). Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile Infection. Gastroenterology 152, 799.e7-811.e7. doi: 10.1053/j.gastro.2016.11.010
122. Panchal, P., Budree, S., Scheeler, A., Medina, G., Seng, M., Wong, W. F., et al. (2018). Scaling safe access to fecal microbiota transplantation: past, present, and future. Curr. Gastroenterol. Rep. 20:14. doi: 10.1007/s11894-018-0619-8
123. Paredes-Sabja, D., Shen, A., and Sorg, J. A. (2014). Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 22, 406-416. doi: 10.1016/j.tim.2014.04.003
124. Pawluk, A., Davidson, A. R., and Maxwell, K. L. (2018). Anti-CRISPR: discovery, mechanism and function. Nat. Rev. Microbiol. 16, 12-17. doi: 10.1038/nrmicro.2017.120
125. Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., et al. (2017). Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment. Pharmacol. Ther. 46, 479-493. doi: 10.1111/apt.14201
126. Ramirez-Vargas, G., Goh, S., and Rodriguez, C. (2018). The novel phages phiCD5763 and phiCD2955 represent two groups of big plasmidial siphoviridae phages of Clostridium difficile. Front. Microbiol. 9:26. doi: 10.3389/fmicb.2018.00026
127. Rao, K., Santhosh, K., Mogle, J. A., Higgins, P. D., and Young, V. B. (2016). Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults. Infect. Dis. 48, 663-669. doi: 10.1080/23744235.2016.1186832
128. Rea, M. C., Clayton, E., O'Connor, P. M., Shanahan, F., Kiely, B., Ross, R. P., et al. (2007). Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J. Med. Microbiol. 56(Pt 7), 940-946. doi: 10.1099/jmm.0.47085-0
129. Rea, M. C., Dobson, A., O'Sullivan, O., Crispie, F., Fouhy, F., Cotter, P. D., et al. (2011). Effect of broad-and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4639-4644. doi: 10.1073/pnas.1001224107
130. Rea, M. C., Sit, C. S., Clayton, E., O'Connor, P. M., Whittal, R. M., Zheng, J., et al. (2010). Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl. Acad. Sci. U.S.A. 107, 9352-9357. doi: 10.1073/pnas.0913554107
131. Reeves, A. E., Koenigsknecht, M. J., Bergin, I. L., and Young, V. B. (2012). Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect. Immun. 80, 3786-3794. doi: 10.1128/IAI.00647-12
132. Ridlon, J. M., Alves, J. M., Hylemon, P. B., and Bajaj, J. S. (2013). Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4, 382-387. doi: 10.4161/gmic.25723
133. Riedel, T., Wittmann, J., Bunk, B., Schober, I., Sproer, C., Gronow, S., et al. (2017). A Clostridioides difficile bacteriophage genome encodes functional binary toxin-associated genes. J. Biotechnol. 250, 23-28. doi: 10.1016/j.jbiotec.2017.02.017
134. Robinson, L. S., Lewis, W. G., and Lewis, A. L. (2017). The sialate O-acetylesterase EstA from gut Bacteroidetes species enables sialidase-mediated cross-species foraging of 9-O-acetylated sialoglycans. J. Biol. Chem. 292, 11861-11872. doi: 10.1074/jbc.M116.769232
135. Roediger, W. E. (1980). Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21, 793-798. doi: 10.1136/gut.21.9.793
136. Rolfe, R. D. (1984). Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infect. Immun. 45, 185-191
137. Salmond, G. P., and Fineran, P. C. (2015). A century of the phage: past, present and future. Nat. Rev. Microbiol. 13, 777-786. doi: 10.1038/nrmicro3564
138. Scaria, J., Chen, J. W., Useh, N., He, H., McDonough, S. P., Mao, C., et al. (2014). Comparative nutritional and chemical phenome of Clostridium difficile isolates determined using phenotype microarrays. Int. J. Infect. Dis. 27, 20-25. doi: 10.1016/j.ijid.2014.06.018
139. Schaefer, L., Auchtung, T. A., Hermans, K. E., Whitehead, D., Borhan, B., and Britton, R. A. (2010). The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology 156(Pt 6), 1589-1599. doi: 10.1099/mic.0.035642-0
140. Schonfeld, P., and Wojtczak, L. (2016). Short-and medium-chain fatty acids in energy metabolism: the cellular perspective. J. Lipid Res. 57, 943-954. doi: 10.1194/jlr.R067629
141. Scott, K. P., Martin, J. C., Duncan, S. H., and Flint, H. J. (2014). Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. FEMS Microbiol. Ecol. 87, 30-40. doi: 10.1111/1574-6941.12186
142. Seekatz, A. M., Rao, K., Santhosh, K., and Young, V. B. (2016). Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 8:47. doi: 10.1186/s13073-016-0298-8
143. Seekatz, A. M., Theriot, C. M., Rao, K., Chang, Y. M., Freeman, A. E., Kao, J. Y., et al. (2018). Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe doi: 10.1016/j.anaerobe.2018.04.001 [Epub ahead of print]
144. Seekatz, A. M., and Young, V. B. (2018). The tangled web of interactions between host, pathogen, and microbiota in Clostridium difficile Infection. Gastroenterology 154, 1573-1576. doi: 10.1053/j.gastro.2018.03.036
145. Sekulovic, O., and Fortier, L. C. (2015). Global transcriptional response of Clostridium difficile carrying the CD38 prophage. Appl. Environ. Microbiol. 81, 1364-1374. doi: 10.1128/AEM.03656-14
146. Sekulovic, O., Meessen-Pinard, M., and Fortier, L. C. (2011). Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J. Bacteriol. 193, 2726-2734. doi: 10.1128/JB.00787-10
147. Shan, J., Ramachandran, A., Thanki, A. M., Vukusic, F. B. I., Barylski, J., and Clokie, M. R. J. (2018). Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells. Sci. Rep. 8:5091. doi: 10.1038/s41598-018-23418-y
148. Shilling, M., Matt, L., Rubin, E., Visitacion, M. P., Haller, N. A., Grey, S. F., et al. (2013). Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on Clostridium difficile. J. Med. Food 16, 1079-1085. doi: 10.1089/jmf.2012.0303
149. Sit, C. S., McKay, R. T., Hill, C., Ross, R. P., and Vederas, J. C. (2011). The 3D structure of thuricin CD, a two-component bacteriocin with cysteine sulfur to alpha-carbon cross-links. J. Am. Chem. Soc. 133, 7680-7683. doi: 10.1021/ja201802f
150. Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., and Kuijper, E. J. (2016). Clostridium difficile infection. Nat. Rev. Dis. Primers 2:16020. doi: 10.1038/nrdp.2016.20
151. Song, Y., Garg, S., Girotra, M., Maddox, C., von Rosenvinge, E. C., Dutta, A., et al. (2013). Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 8:e81330. doi: 10.1371/journal.pone.0081330
152. Sorg, J. A., and Sonenshein, A. L. (2008). Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190, 2505-2512. doi: 10.1128/JB.01765-07
153. Sorg, J. A., and Sonenshein, A. L. (2009). Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J. Bacteriol. 191, 1115-1117. doi: 10.1128/JB.01260-08
154. Sorg, J. A., and Sonenshein, A. L. (2010). Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192, 4983-4990. doi: 10.1128/JB.00610-10
155. Spinler, J. K., Auchtung, J., Brown, A., Boonma, P., Oezguen, N., Ross, C. L., et al. (2017). Next-Generation probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect. Immun. 85:e00303-17. doi: 10.1128/IAI.00303-17
156. Staley, C., Weingarden, A. R., Khoruts, A., and Sadowsky, M. J. (2017). Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl. Microbiol. Biotechnol. 101, 47-64. doi: 10.1007/s00253-016-8006-6
157. Studer, N., Desharnais, L., Beutler, M., Brugiroux, S., Terrazos, M. A., Menin, L., et al. (2016). Functional intestinal bile Acid 7alpha-Dehydroxylation by Clostridium scindens associated with protection from Clostridium difficile infection in a gnotobiotic mouse model. Front Cell Infect. Microbiol. 6:191. doi: 10.3389/fcimb.2016.00191
158. Su, W. J., Waechter, M. J., Bourlioux, P., Dolegeal, M., Fourniat, J., and Mahuzier, G. (1987). Role of volatile fatty acids in colonization resistance to Clostridium difficile in gnotobiotic mice. Infect. Immun. 55, 1686-1691
159. Tagg, J. R., Dajani, A. S., and Wannamaker, L. W. (1976). Bacteriocins of gram-positive bacteria. Bacteriol. Rev. 40, 722-756
160. Tam, J., Beilhartz, G. L., Auger, A., Gupta, P., Therien, A. G., and Melnyk, R. A. (2015). Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. Chem. Biol. 2, 175-185. doi: 10.1016/j.chembiol.2014.12.010
161. Tedelind, S., Westberg, F., Kjerrulf, M., and Vidal, A. (2007). Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J. Gastroenterol. 13, 2826-2832. doi: 10.3748/wjg.v13.i20.2826
162. Terveer, E. M., Crobach, M. J., Sanders, I. M., Vos, M. C., Verduin, C. M., and Kuijper, E. J. (2017a). Detection of Clostridium difficile in feces of asymptomatic patients admitted to the hospital. J. Clin. Microbiol. 55, 403-411. doi: 10.1128/JCM.01858-16
163. Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Mulder, C. J. J., Kuijper, E. J., Keller, J. J., et al. (2018). Faecal microbiota transplantation in clinical practice. Gut 67:196. doi: 10.1136/gutjnl-2017-313909
164. Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J., Bauer, M. P., van Nood, E., et al. (2017b). How to: establish and run a stool bank. Clin. Microbiol. Infect. 23, 924-930. doi: 10.1016/j.cmi.2017.05.015
165. Thanissery, R., Winston, J. A., and Theriot, C. M. (2017). Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. Anaerobe 45, 86-100. doi: 10.1016/j.anaerobe.2017.03.004
166. Theriot, C. M., Koenigsknecht, M. J., Carlson, P. E. Jr., Hatton, G. E., Nelson, A. M., Li, B., et al. (2014). Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5:3114. doi: 10.1038/ncomms4114
167. Theriot, C. M., and Young, V. B. (2015). Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu. Rev. Microbiol. 69, 445-461. doi: 10.1146/annurev-micro-091014-104115
168. Tracanna, V., de Jong, A., Medema, M. H., and Kuipers, O. P. (2017). Mining prokaryotes for antimicrobial compounds: from diversity to function. FEMS Microbiol. Rev. 41, 417-429. doi: 10.1093/femsre/fux014
169. Tsukahara, T., and Ushida, K. (2002). Succinate accumulation in pig large intestine during antibiotic-associated diarrhea and the constitution of succinate-producing flora. J. Gen. Appl. Microbiol. 48, 143-154. doi: 10.2323/jgam.48.143
170. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415. doi: 10.1056/NEJMoa1205037
171. van Nuenen, M. H. M. C., Diederick Meyer, P., and Venema, K. (2003). The effect of various inulins and Clostridium difficile on the metabolic activity of the human colonic microbiota in vitro. Microb. Ecol. Health Dis. 15, 137-144. doi: 10.1080/08910600310018959
172. Weingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., et al. (2014). Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G310-G319. doi: 10.1152/ajpgi.00282.2013
173. Weingarden, A. R., Chen, C., Zhang, N., Graiziger, C. T., Dosa, P. I., Steer, C. J., et al. (2016a). Ursodeoxycholic Acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J. Clin. Gastroenterol. 50, 624-630. doi: 10.1097/MCG.0000000000000427
174. Weingarden, A. R., Dosa, P. I., DeWinter, E., Steer, C. J., Shaughnessy, M. K., Johnson, J. R., et al. (2016b). Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One 11:e0147210. doi: 10.1371/journal.pone.0147210
175. Wilson, K. H. (1983). Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J. Clin. Microbiol. 18, 1017-1019
176. Wilson, K. H., and Perini, F. (1988). Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 56, 2610-2614
177. Woodworth, M. H., Neish, E. M., Miller, N. S., Dhere, T., Burd, E. M., Carpentieri, C., et al. (2017). Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent Clostridium difficile infection. J. Clin. Microbiol. 55, 1002-1010. doi: 10.1128/JCM.02327-16
178. Yamakawa, K., Kamiya, S., Meng, X. Q., Karasawa, T., and Nakamura, S. (1994). Toxin production by Clostridium difficile in a defined medium with limited amino acids. J. Med. Microbiol. 41, 319-323. doi: 10.1099/00222615-41-5-319
179. Yang, H. T., Chen, J. W., Rathod, J., Jiang, Y. Z., Tsai, P. J., Hung, Y. P., et al. (2017). Lauric acid is an inhibitor of Clostridium difficile growth in vitro and reduces inflammation in a mouse infection model. Front. Microbiol. 8:2635. doi: 10.3389/fmicb.2017.02635
180. Zackular, J. P., Chazin, W. J., and Skaar, E. P. (2015). Nutritional immunity: S100 proteins at the host-pathogen interface. J. Biol. Chem. 290, 18991-18998. doi: 10.1074/jbc.R115.645085
181. Zackular, J. P., Moore, J. L., Jordan, A. T., Juttukonda, L. J., Noto, M. J., Nicholson, M. R., et al. (2016). Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat. Med. 22, 1330-1334. doi: 10.1038/nm.4174
182. Zackular, J. P., and Skaar, E. P. (2018). The role of zinc and nutritional immunity in Clostridium difficile infection. Gut Microbes doi: 10.1080/19490976.2018.1448354 [Epub ahead of print]
183. Zhang, F., Luo, W., Shi, Y., Fan, Z., and Ji, G. (2012). Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol. 107, 1755-1756. doi: 10.1038/ajg.2012.251
184. Zuo, T., Wong, S. H., Lam, K., Lui, R., Cheung, K., Tang, W., et al. (2018). Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 67, 634-643. doi: 10.1136/gutjnl-2017-313952